DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.

Brand-name GLP-1
Noom Med pairs Noom psychology-based coaching with clinician-prescribed GLP-1.
Tap your plan for prior authorization criteria, copay range, and step therapy rules.
One-tap side-by-side. Score + price + side-effect profile.
Answer a 5-minute health intake. A licensed clinician reviews your history, BMI, comorbidities, and prior medications.
If clinically appropriate, your clinician writes a prescription. Insurance PA submitted on your behalf, or cash-pay routed to manufacturer direct channels.
Medication ships from a verified pharmacy. Monthly check-ins for titration, side-effect management, and dose adjustments.
Pick your insurance situation. Your monthly cost + best route update live.
Estimates only. Final out-of-pocket varies by plan tier, formulary, deductible status, and pharmacy.
Placeholder visuals. Real product imagery shipping pending DEA-compliant photo licensing.
We require a 12-section template before publishing. This page covers 1 of 12.
As bariatric medicine specialist, I check every claim on this review against FDA labeling, peer-reviewed trial data, and current clinical guidelines. If something's off, we publish a correction.
Six axes, one sentence each. No black-box rating — how we score.
Most providers discount longer commitments. Estimate effective monthly cost across plan lengths.
Discount assumptions are based on common industry tiers (5% at 3 mo, 10% at 6 mo, 17% at 12 mo). Actual provider discounts vary — confirm at checkout.
From $149/monthly
See current pricing and program details directly from the provider.
Editorial review independent of affiliate status. Affiliate disclosure on every page.
FDA issued warning letters to Hims & Hers and several compounding pharmacies over weight-loss advertising claims and compounded semaglutide / tirzepatide marketing post-shortage resolution. Editorial: providers featured here have been reviewed for compliance with current FDA rules.
Read the source ↗FDA confirmed both molecules off the official shortage list. 503A and 503B compounding pharmacies can no longer compound semaglutide or tirzepatide except for documented individual medical-necessity cases. Patients on compounded GLP-1s should plan to transition to brand or off-label scripts.
Read the source ↗We track regulatory actions and surface them publicly, even when they involve advertised partners. Editorial rankings reflect verification, not commission.
Dated record of factual corrections and material updates to this page. We publish corrections rather than silently edit. Trust signal, not legal compliance.
Added editorial blocks: weight-loss projection slider, savings card workflow, side-effect onset chart, FDA regulatory transparency, numbered citations, plateau diagnostic cross-link. Refreshed AI product photography to 1536x1024 editorial-grade renders.
Added inline Jargon tooltip system across editorial body. Glossary appendix shows medical terms used per drug.
FAQ schema (FAQPage JSON-LD) added per review. People-also-ask block cross-links to Q&A library.
Quick reference for medical and regulatory terms above. Each term links to a longer explainer if you want deeper context.
Other products in the same category, ranked by our editorial score.